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The purpose of this analysis of health economic studies in the field of oncology was to investigate among sponsored studies whether
any relationship could be established between the type of sponsorship and (1) type of economic analysis, (2) health technology
assessed, (3) sensitivity analysis performed, (4) publication status, and (5) qualitative conclusions about costs. The Health Economic
Evaluations Database (HEED, version 1995–2000) was searched on the basis of oncological ICD-9 codes, sponsorship, and
comparative studies. This search yielded a total of 150 eligible articles. Their evaluations were prepared independently by two
investigators, on the basis of specific criteria. When evaluators disagreed, a third investigator provided a deciding evaluation. There
was no statistically significant relationship between the type of sponsorship and sensitivity analysis performed (P¼0.29) or publication
status (P¼0.08). However, we found a significant relationship between the types of sponsorship and of economic analysis
(P¼0.004), the health technology assessed (Po0.0001), and qualitative cost assessment (P¼0.002). Studies with industrial
sponsorship were 2.56 (99% lower confidence interval (CI)¼1.28) times more likely to involve cost-minimisation analyses, were 0.04
(99% higher CI¼0.39) times less likely to investigate diagnostic screening methods, and were 1.86 (99% lower CI¼1.21) times more
likely to reach positive qualitative conclusions about costs than studies supported by nonprofit organisations. In conclusion, our results
suggest that there is a greater probability that industry-sponsored economic studies in the field of oncology tend to be cost-
minimisation analyses, to investigate less likely diagnostic screening methods, and to draw positive qualitative conclusions about costs,
as compared to studies supported by nonprofit organisations.
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There has long been discussion as to whether commercial
sponsorship of clinical studies produces a conflict of interests
(Davidson, 1986; Rochon et al, 1994; Krimsky and Rothenberg,
1998; Smith, 1998; Stelfox et al, 1998; Montaner et al, 2001; Morin
et al, 2002). However, only two applied studies deal with this issue
for health economic studies conducted in the field of oncology.
Friedberg et al (1999) found that, in the case of new drugs
developed for oncological use (including haematopoietic growth
factors, antiemetics, taxanes), pharmaceutical sponsorship of
economic analyses was associated with a low likelihood of
reporting unfavourable results. Subsequently, however, the same
authors moderated these conclusions about costs in a comparison
of industry vs nonprofit-sponsored economic analyses of six novel
drugs used in oncology (Knox et al, 2001). After reviewing all the
available pharmacoeconomic reports, they established the differ-
ences in study reporting – but not in the types of journals in which
the studies were published – between pharmaceutical company-
and non-profit-sponsored studies. They concluded that these
results, and in particular the observed differences in data
generalisability, may have accounted in part for their previous
conclusions about costs that unfavourable results were less likely
to be reported from pharmaceutical-sponsored studies.
Therefore, it was the purpose of the present investigation to
determine a statistically significant relationship between the type
of sponsorship and (1) type of economic analysis, (2) the health
technology assessed (e.g., drugs, screening, or surgery), (3)
sensitivity analysis performed, (4) publication status, and (5)
qualitative conclusions about costs in health economic studies
conducted in the field of oncology.
MATERIALS AND METHODS
Using the ICD-9 codes (140–165, 170–175, 179–184, 185–208,
and 284), all health economic publications in the field of oncology
(n¼1381) were identified in the Health Economic Evaluations
Database (HEED, Version 1995–2000). Databases covered in
HEED are Medline and Embase. After eliminating redundant
publications (n¼161), letters-to-editors, review articles, editorials
and methodological studies (n¼329), a total of 891 applied studies
remained. We excluded all studies (n¼1603) not disclosing a
sponsor, so as to exclude studies that were not published or did
not reveal the sponsor to the editors in order to have indisputable
data for our study question. The reason that we did not send letters
to the studies where no sponsor was indicated to see who actually
sponsored the study was that if someone has not disclosed any
sponsor for a sponsored study in his publication he has done a
scientific misconduct and it is unlikely that he will admit this.
For 288 applied studies, a sponsor was named. After the
exclusion of studies that did not compare alternative health Received 27 January 2003; revised 23 July 2003; accepted 5 August 2003
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ltechnologies (cost-analysis (n¼24), cost-consequence (n¼98),
and cost-of-illness (n¼16) studies), a total of 150 sponsored
studies involving comparisons remained (Figure 1). They were
evaluated on the basis of the criteria type sponsorship, type of
economic analysis, health technology assessed, sensitivity analysis
performed, publication status, and qualitative conclusions about
costs.
An investigation was compared to have been industry-spon-
sored or to have been sponsored by nonprofit organisations if, in
the publication, it was disclosed that all or part of the support
provided originated from industry, respectively, from nonprofit
organisations. For assessing the type of economic analysis used,
distinctions were made among cost-effectiveness analysis (mea-
sures benefits of different medical treatments having a common
health outcome (e.g., life years saved) and computes a cost-
effectiveness measure ratio for comparison), cost-benefit analysis
(measures costs and benefits of a medical treatment in financial
units and computes a net monetary gain/loss or a cost–benefit
ratio), cost-utility analysis (measures benefits of different medical
treatments in utility-weighted life years (quality-adjusted life years,
QALYs) and computes a cost–utility ratio for comparison), and
cost-minimisation analyses (finds the least costly medical treat-
ment among those shown or assumed to be of equal medical
benefit).
Studies were also differentiated into categories for health
technology assessed: pharmacokinetic monitoring, supportive
care, medical devices, diagnostic, drugs, screening, and surgery.
Publication status as a marker for the publication rated studies as
published in peer-reviewed or non-peer-reviewed journals. Since
even within the peer-reviewed literature, the quality of publica-
tions is highly variable, a sensitivity analysis (one-way or multiple-
way) was chosen from the checklist for this subject, developed by
Drummond (Drummond and Jefferson, 1996) as an additional
marker for the study quality. Sensitivity analysis (one-way or
multiple-way) was chosen, because it is a process through which
the robustness of an economic model is assessed by examining the
changes in results of the analysis when key variables are varied
over a specified range. Therefore, a yes/no decision was made as to
whether a sensitivity analysis had been performed. Qualitative
conclusions about costs were evaluated as positive, negative or
neutral. Conclusions about costs were assumed to be positive if
there was a statement in the publication that the health technology
assessed reduced costs, was cost effective, cost beneficial, or cost
utilitarian, and negative if the technology assessed had higher cost,
and was not cost effective, cost beneficial, or cost utilitarian. When
there was neither a positive nor a negative statement about the
outcome of cost assessment, it was assumed to be neutral for the
purpose of the present analyses. All evaluations were made
independently by two investigators (MH and HK). If the
investigators disagreed over the evaluation of any article, a third
investigator (DS) made a deciding evaluation.
Relationships between the type of sponsorship and type of
economic evaluation, health technology assessed, sensitivity
analysis performed, publication status, and qualitative conclusions
about costs were analysed using Fisher’s exact test (the modifica-
tions by Metha for tables larger than 2 2) to provide a two-sided
probability (Po0.05, against the null hypothesis of no relationship
was considered significant).
In a second analysis, large tables (analysis type, health
technology, and conclusions about costs) were recombined to
provide 2 2 tables. That is, for dealing with the relative risk
(industry vs nonprofit) for ‘cost-minimisation’ analyses, all other
types were collected in one category called ‘other’. The reason
behind the collapsing into 2 2 tables was not the (two-sided) P-
value itself, but the one-sided P-value, because Fisher’s exact test is
inherently two-sided (at least for tables larger than 2 2);
furthermore by collapsing into 2 2 tables, we could construct
confidence intervals (CIs) for the relative risk for ‘cost minimisa-
tion,’ which is not possible for larger tables. Hence, by using these
2 2 tables, one-sided 99% CIs for the relative risks were
calculated by computing P-values. A (small) one-sided P-value
allows to conclude that one sponsoring type provides significant
larger (or smaller) numbers of, for example, positive outcomes.
The higher confidence level of 99% was chosen so as to insure that
simultaneous computing of two (ore more) intervals provides
reasonable small overall error probabilities and does not lead to
high error probabilities. No formal adjustment was made for
multiple comparisons and, therefore, the 99% CIs have descriptive
interpretation rather than being used for hypothesis testing. All
computations were executed by SAS 8.2 Software (SAS Institute
Inc., Cary, NC, USA).
RESULTS
The sponsor of 71% (106 out of 150) of the studies evaluated was a
nonprofit organisation; the other 44 studies (29%) were supported
by an industrial sponsor in whole or part. Of the 150 studies, 63%
were cost-effectiveness analyses, 22% cost-minimisation analyses,
12% cost-utility analyses, and 3% involved cost–benefit analyses.
The treatments assessed were drugs in 41% of the 150 studies,
screening procedures in 29%, diagnostic methods in 14%, surgery
in 12%, care in 2% (3), medical devices in 2%, and pharmacoki-
netic monitoring in 1%. In 48% of the 150 studies, there was no
sensitivity analysis, and nearly all (89%) were published in peer-
reviewed journals. The two primary evaluators agreed on the
classification in 82% of the cases, and the third investigator was
required to determine the classification of the other 18%.
The type of sponsorship was not significantly associated with
sensitivity analysis or publication status (P¼0.29, 0.08). However,
there was a demonstrable relationship between the type of
sponsorship and type of economic analysis (P¼0.004), health
technology assessed (Po0.0001), and qualitative conclusions
about costs (P¼0.002) (Table 1). Compared to studies sponsored
by nonprofit organisations, industry-sponsored studies were 2.56
(lower 99% CI¼1.28, therefore 41.00) times more likely to be
cost-minimisation analyses and 0.60 (higher 99% CI¼0.92, or
o1.00) times less likely to be cost-effectiveness analyses. They
were also 3.45 (lower 99% CI¼2.24) times more likely to
investigate drugs and 0.04 (higher 99% CI¼0.39) times less likely
to investigate screening. In comparison with the studies sponsored
by nonprofit-making organisations, they were 1.86 (lower 99%
CI¼1.21) times more likely to reach positive qualitative conclu-
sions about costs.
DISCUSSION
This investigation encountered several interesting relationships
between the type of sponsorship and the outcome of health
economic studies conducted in the field of oncology, despite some
limitations. We emphasise that we did not investigate individual
Redundant studies
n = 161
No sponsor named
n = 603
Noncomparative studies
n = 138
Comparative studies
n = 150
Sponsor named
n = 288
Applied studies
n = 891
Not applied studies
n = 329
Oncological studies
n = 1.381
Figure 1 Flow diagram of the studies.
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limiting studies considered to those in which information on
financial support was provided. In addition, we did not stratify any
subgroup based on the quality of the studies.
Our results show that, irrespective of the study sponsor, three
times as many studies with positive rather than negative
conclusions about costs (62 vs 23 studies) were published. This
outcome can be attributed to the fact that in health economic
research, as in other areas of medicine (Callahan et al, 1998), there
is a preference for publishing studies with positive results
(publication bias). Although this practice is considered a scientific
misconduct, withholding the publication of unfavourable results is
not uncommon (Bodenheimer, 2000). Furthermore, industry-
sponsored studies were 1.9 times more likely to have positive
qualitative conclusions about costs than studies sponsored by
nonprofit organisations. This relationship can be attributed to a
sponsorship bias. Industry-sponsored clinical studies more
frequently compare novel treatments against a placebo than
against drugs that are known to be effective (Djulbegovic et al,
2000). Therefore, it can be assumed that companies may simply
avoid conducting head-to-head economic trials, particularly when
they are unlikely to reveal the superiority of a new treatment or
drug.
In comparison with studies sponsored by nonprofit organisa-
tions, industry-sponsored studies were 1.9 times more likely to be
cost-minimisation analyses, and 2.5 times less likely to be cost-
effectiveness analyses. The reason for these relationships becomes
apparent when the definition of cost-minimisation analysis is
considered. Such analyses involve comparisons of equieffective
alternatives on the basis of net costs, with the aim of determining
the less costly option. If it can be demonstrated in a cost-
minimisation analysis that, with identical clinical outcome, the
sponsor’s drug reduces costs of treatment compared to a
competitor’s drug, the sponsor can readily expand market share.
Drug companies can use such successful trials to market their
products. This factor could also explain the most important
demonstrated association between industry sponsorship and
positive qualitative cost assessment, if cost-minimisation analysis
is inherently more likely to lead to a positive assessment.
Sensitivity analysis is useful for determining the quality of
investigations in health economics. It is a process through which
the robustness of an economic study is assessed by examining the
changes in results of the analysis when key variables are varied
over a specified range. However, in nearly half (72/150¼46%) of
the present studies, no sensitivity analysis was conducted,
irrespective of the type of study sponsor. On the basis of this
criterion alone, almost half of all health economic studies
conducted in the field of oncology have an evidence level below
3b, according to the classification system of the Oxford Centre for
Evidence-based Medicine (2002). They thus have the same value
for health economic analysis as case series (evidence level 4) or
expert opinions without critical appraisal (evidence level 5) have
for therapeutic aspects.
In comparison to studies sponsored by nonprofit organisations,
the industry-sponsored studies were 3.45 times more likely to
involve drugs and 25 (1/0.04) times less likely to involve evaluation
of diagnostic screening methods. For industry, in contrast with
nonprofit organisations, the economic evaluation of screening
methods is usually of limited financial interest. However, in view of
the fact that a medical treatment exhibits a reduction of its
marginal utility with increasing exploitation, the economic
evaluation of screening procedures is of particular interest. Only
by means of health economics assessment is it possible to provide
the preparatory groundwork for the decision on who should be
screened, how often, and at what cost.
In order to counter the risk that the type of sponsorship might
influence health economic analyses, it is necessary to improve the
quality of such studies. Economic analyses should: (1) be based on
clinically acceptable costs or alternatives, (2) conduct a systematic
review of the evidence, and (3) include a multiway sensitivity
analysis (simultaneous variation of several key variables to test the
robustness of the result), in order to achieve an evidence level
comparable to that of randomised controlled clinical trials (RCTs)
[12]. Furthermore, full disclosure of all financial interests involved
in health economic studies should be provided routinely.
As we could demonstrate, the potential for bias may exist on
multiple levels. Therefore, establishing checks and balances for
academic–industry partnership, as it is proposed for clinical
studies (Chopra, 2003), may help to mitigate the potential for bias
in health economics.
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